149 related articles for article (PubMed ID: 23032070)
1. Effects of levetiracetam as a monotherapy on bone mineral density and biochemical markers of bone metabolism in patients with epilepsy.
Koo DL; Joo EY; Kim D; Hong SB
Epilepsy Res; 2013 Mar; 104(1-2):134-9. PubMed ID: 23032070
[TBL] [Abstract][Full Text] [Related]
2. Effect of oxcarbazepine on bone mineral density and biochemical markers of bone metabolism in patients with epilepsy.
Koo DL; Hwang KJ; Han SW; Kim JY; Joo EY; Shin WC; Lee HW; Seo DW; Hong SB
Epilepsy Res; 2014 Mar; 108(3):442-7. PubMed ID: 24507862
[TBL] [Abstract][Full Text] [Related]
3. Preliminary evidence for gender effects of levetiracetam monotherapy duration on bone health of patients with epilepsy.
Artemiadis AK; Lambrinoudaki I; Voskou P; Tsivgoulis G; Safouris A; Bougea A; Giannopoulos S; Gatzonis S; Triantafyllou N
Epilepsy Behav; 2016 Feb; 55():84-6. PubMed ID: 26773675
[TBL] [Abstract][Full Text] [Related]
4. Effects of zonisamide monotherapy on bone health in drug-naive epileptic patients.
Koo DL; Nam H
Epilepsia; 2020 Oct; 61(10):2142-2149. PubMed ID: 32944954
[TBL] [Abstract][Full Text] [Related]
5. Levetiracetam and lamotrigine effects as mono- and polytherapy on bone mineral density in epileptic patients.
El-Haggar SM; Mostafa TM; Allah HMS; Akef GH
Arq Neuropsiquiatr; 2018 Jul; 76(7):452-458. PubMed ID: 30066796
[TBL] [Abstract][Full Text] [Related]
6. The effect of levetiracetam on rat bone mass, structure and metabolism.
Fekete S; Simko J; Gradosova I; Malakova J; Zivna H; Palicka V; Zivny P
Epilepsy Res; 2013 Nov; 107(1-2):56-60. PubMed ID: 24035343
[TBL] [Abstract][Full Text] [Related]
7. Effects of valproate, carbamazepine, and levetiracetam on the antioxidant and oxidant systems in epileptic patients and their clinical importance.
Varoglu AO; Yildirim A; Aygul R; Gundogdu OL; Sahin YN
Clin Neuropharmacol; 2010 May; 33(3):155-7. PubMed ID: 20502135
[TBL] [Abstract][Full Text] [Related]
8. Effects of levetiracetam monotherapy on the cognitive function of epilepsy patients.
Koo DL; Hwang KJ; Kim D; Kim YJ; Kim JY; Shin W; Kim MR; Joo EY; Lee JM; Hong SB
Eur Neurol; 2013; 70(1-2):88-94. PubMed ID: 23839084
[TBL] [Abstract][Full Text] [Related]
9. Effect of levetiracetam monotherapy on background EEG activity and cognition in drug-naïve epilepsy patients.
Cho JR; Koo DL; Joo EY; Yoon SM; Ju E; Lee J; Kim DY; Hong SB
Clin Neurophysiol; 2012 May; 123(5):883-91. PubMed ID: 22000706
[TBL] [Abstract][Full Text] [Related]
10. Levetiracetam, phenytoin, and valproate act differently on rat bone mass, structure, and metabolism.
Nissen-Meyer LS; Svalheim S; Taubøll E; Reppe S; Lekva T; Solberg LB; Melhus G; Reinholt FP; Gjerstad L; Jemtland R
Epilepsia; 2007 Oct; 48(10):1850-60. PubMed ID: 17634065
[TBL] [Abstract][Full Text] [Related]
11. Effects of new antiepileptic drugs on circulatory markers for vascular risk in patients with newly diagnosed epilepsy.
Kim DW; Lee SY; Shon YM; Kim JH
Epilepsia; 2013 Oct; 54(10):e146-9. PubMed ID: 23980720
[TBL] [Abstract][Full Text] [Related]
12. Relationship between bone density and levetiracetam monotherapy in epilepsy patients.
Gözükızıl ST; Aydın Z; Yalçın AD
Clin Neurol Neurosurg; 2022 Jul; 218():107270. PubMed ID: 35623138
[TBL] [Abstract][Full Text] [Related]
13. A 6-month longitudinal study of bone mineral density with antiepileptic drug monotherapy.
Kim SH; Lee JW; Choi KG; Chung HW; Lee HW
Epilepsy Behav; 2007 Mar; 10(2):291-5. PubMed ID: 17224308
[TBL] [Abstract][Full Text] [Related]
14. Levetiracetam.
Krishna K; Raut AL; Gohel KH; Dave P
J Assoc Physicians India; 2011 Oct; 59():656-8. PubMed ID: 22479748
[TBL] [Abstract][Full Text] [Related]
15. Bone mineral density following long-term use of antiepileptic drugs in a tropical Asian country.
Phabphal K; Limapichat K; Sathirapanya P; Setthawatcharawanich S; Leelawattana R; Thammakumpee N; Thamaprasit A; Geater A
Epileptic Disord; 2008 Sep; 10(3):213-8. PubMed ID: 18782690
[TBL] [Abstract][Full Text] [Related]
16. The bone mineral content alterations in pediatric patients medicated with levetiracetam, valproic acid, and carbamazepine.
Serin HM; Koç ZP; Temelli B; Esen İ
Epilepsy Behav; 2015 Oct; 51():221-4. PubMed ID: 26298867
[TBL] [Abstract][Full Text] [Related]
17. Prevention of bone loss and vertebral fractures in patients with chronic epilepsy--antiepileptic drug and osteoporosis prevention trial.
Lazzari AA; Dussault PM; Thakore-James M; Gagnon D; Baker E; Davis SA; Houranieh AM
Epilepsia; 2013 Nov; 54(11):1997-2004. PubMed ID: 24010637
[TBL] [Abstract][Full Text] [Related]
18. Short-term effect of levetiracetam monotherapy on haematological parameters in children with epilepsy: a prospective study.
Dinopoulos A; Attilakos A; Paschalidou M; Tsirouda M; Garoufi A; Moustaki M; Siafakas N; Papaevangelou V
Epilepsy Res; 2014 May; 108(4):820-3. PubMed ID: 24630047
[TBL] [Abstract][Full Text] [Related]
19. Effect of switching hepatic enzyme-inducer antiepileptic drug to levetiracetam on bone mineral density, 25 hydroxyvitamin D, and parathyroid hormone in young adult patients with epilepsy.
Phabphal K; Geater A; Limapichat K; Sathirapanya P; Setthawatcharawanich S; Leelawattana R
Epilepsia; 2013 Jun; 54(6):e94-8. PubMed ID: 23586623
[TBL] [Abstract][Full Text] [Related]
20. Effect of long-term valproate monotherapy on bone mineral density in adults with epilepsy.
Triantafyllou N; Lambrinoudaki I; Armeni E; Evangelopoulos EM; Boufidou F; Antoniou A; Tsivgoulis G
J Neurol Sci; 2010 Mar; 290(1-2):131-4. PubMed ID: 20056251
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
